Subsynaptic Distribution, Lipid Raft Targeting and G Protein-Dependent Signalling of the Type 1 Cannabinoid Receptor in Synaptosomes from the Mouse Hippocampus and Frontal Cortex by Saumell Esnaola, Miquel et al.
molecules
Article
Subsynaptic Distribution, Lipid Raft Targeting and G
Protein-Dependent Signalling of the Type 1 Cannabinoid
Receptor in Synaptosomes from the Mouse Hippocampus
and Frontal Cortex
Miquel Saumell-Esnaola 1,2,3 , Sergio Barrondo 1,2,4, Gontzal García del Caño 2,5, María Aranzazu Goicolea 6,




Barrondo, S.; García del Caño, G.;
Goicolea, M.A.; Sallés, J.; Lutz, B.;
Monory, K. Subsynaptic Distribution,
Lipid Raft Targeting and G Protein-
Dependent Signalling of the Type 1
Cannabinoid Receptor in
Synaptosomes from the Mouse
Hippocampus and Frontal Cortex.
Molecules 2021, 26, 6897. https://
doi.org/10.3390/molecules26226897
Academic Editors: Mauro Maccarrone
and Eva de Lago Femia
Received: 14 October 2021
Accepted: 11 November 2021
Published: 16 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country UPV/EHU,
01006 Vitoria-Gasteiz, Spain; miquel.saumell@ehu.eus (M.S.-E.); sergio.barrondo@ehu.eus (S.B.);
joan.salles@ehu.eus (J.S.)
2 Bioaraba, Neurofarmacología Celular y Molecular, 01009 Vitoria-Gasteiz, Spain; gontzal.garcia@ehu.eus
3 Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University Mainz,
55128 Mainz, Germany; beat.lutz@uni-mainz.de
4 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain
5 Department of Neurosciences, Faculty of Pharmacy, University of the Basque Country UPV/EHU,
01006 Vitoria-Gasteiz, Spain
6 Department of Analytical Chemistry, Faculty of Pharmacy, University of the Basque Country UPV/EHU,
01006 Vitoria-Gasteiz, Spain; mariaaranzazu.goicolea@ehu.eus
* Correspondence: monory@uni-mainz.de; Tel.: +49-6131-39-24551
Abstract: Numerous studies have investigated the roles of the type 1 cannabinoid receptor (CB1) in
glutamatergic and GABAergic neurons. Here, we used the cell-type-specific CB1 rescue model in
mice to gain insight into the organizational principles of plasma membrane targeting and Gαi/o
protein signalling of the CB1 receptor at excitatory and inhibitory terminals of the frontal cortex
and hippocampus. By applying biochemical fractionation techniques and Western blot analyses
to synaptosomal membranes, we explored the subsynaptic distribution (pre-, post-, and extra-
synaptic) and CB1 receptor compartmentalization into lipid and non-lipid raft plasma membrane
microdomains and the signalling properties. These data infer that the plasma membrane partitioning
of the CB1 receptor and its functional coupling to Gαi/o proteins are not biased towards the cell
type of CB1 receptor rescue. The extent of the canonical Gαi/o protein-dependent CB1 receptor
signalling correlated with the abundance of CB1 receptor in the respective cell type (glutamatergic
versus GABAergic neurons) both in frontal cortical and hippocampal synaptosomes. In summary,
our results provide an updated view of the functional coupling of the CB1 receptor to Gαi/o proteins
at excitatory and inhibitory terminals and substantiate the utility of the CB1 rescue model in studying
endocannabinoid physiology at the subcellular level.
Keywords: type 1 cannabinoid receptor CB1; cholesterol; hippocampus; frontal cortex; synaptosomes;
rescue model; anti-CB1 antibody
1. Introduction
The physiological role of the activation of the presynaptically located CB1 recep-
tor in balancing excitatory and inhibitory neurotransmission is essential for various be-
haviours [1–4]. Various mouse lines have been developed that rescue CB1 receptor ex-
pression specifically in dorsal telencephalic glutamatergic neurons (Glu-CB1-RS) and in
forebrain GABAergic neurons (GABA-CB1-RS) [5,6]. Importantly, the results demonstrated
that rescue strategies re-establish existing levels of CB1 receptors expressed in glutamatergic
and GABAergic cell types accurately, without the interference of additional cells expressing
CB1 receptors [5–7]. Moreover, this cell-type selective CB1 receptor expression has made
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it possible to define the contributions of both glutamatergic and GABAergic CB1 recep-
tor to the tetrad effects of ∆9-tetrahydrocannabinol [8]. Interestingly, this genetic rescue
approach has revealed functions of CB1 receptor subpopulations that remain undetected
when relying solely on a conditional knockout approach [8,9]. Previously, we have ad-
dressed cell-type specificity of the functional CB1 receptor coupling to Gαi/o proteins in
hippocampal homogenates of conditional knockout mice [10]. Data showed that the CB1
receptor was more efficiently coupled to Gαi/o protein signalling in glutamatergic neurons
than in GABAergic neurons [10]. The cell type-specific effects on agonist efficacy at the
CB1 receptor observed in conditional mutant mouse lines prompted us to focus on CB1
receptors located specifically at nerve terminals, a physiologically relevant location, and to
the proximal components of the signalling machinery in this subsynaptic compartment, the
Gαi/o protein family. In this context, biochemical constraints related to the activation of G
protein coupled receptors (GPCRs), such as membrane lipid composition, and specifically
the effects of membrane cholesterol abundance, are highly relevant as well. We decided
to explore these concepts in synaptosomal fractions purified from frontal cortex and hip-
pocampus derived from Glu-CB1-RS and GABA-CB1-RS mouse lines [5,6]. Moreover, we
took advantage of biochemical fractionation techniques to separate either the subsynaptic
domains (pre-, post-, and extra-synaptic fractions) [11] that have been successfully applied
to the study of the subsynaptic location of CB1 receptor in rat striatal synaptosomes [12] or
the biochemically defined lipid and non-lipid raft plasma membrane microdomains [13].
We have also explored the effects of membrane cholesterol on CB1 signalling by the choles-
terol depletion agent methyl-β-cyclodextrin (MβCD). Although previous results using
electron microscopy, a method that preserves the structure of the synapse, demonstrated
that rescue strategies re-establish existing CB1 receptor levels expressed in glutamatergic
and GABAergic cells [7], the accessibility of the CB1 receptor epitopes by large molecules
such as antibodies could hamper their detection. Here, an alternative approach was used,
which takes advantage of biochemical fractionation techniques allowing the immunological
detection of solubilized plasma membrane proteins by a subsequent Western blot analysis.
The results obtained provide an updated view of the functional coupling of the CB1
receptor to the canonical Gαi/o protein signalling at excitatory and inhibitory terminals of
the mouse frontal cortex and hippocampus, and demonstrate the potential of our approach
to gain insight into the organizational principles of the CB1 receptor plasma membrane
location and Gαi/o protein signalling.
2. Results
2.1. Validation of the Enriched Synaptosomal Fraction from Mouse Frontal Cortex
Synaptosomes were purified using a fractionation protocol based on sucrose gradi-
ents and differential centrifugation, which allowed the separation of synaptic terminals
from other particles of different subcellular origin according to their density. To assess
the suitability of the synaptosome enriched fraction, Western blot and epifluorescence
microscope techniques were applied. To determine the purity of the synaptosomal frac-
tion (SYN), Western blot assays were carried out using antibodies raised against several
proteins that have been used as markers of specific sub-cellular compartments. As shown
in the Supplementary Figure S1, the immunoreactivity for different synaptic proteins
(synaptophysin, syntaxin 1a, and the NMDA receptor subunit NR1) was enriched in the
synaptosomal fraction. The immunoreactivity of Ras-related protein (Rab11b), which is
found in synaptic endosomes among other cellular compartments, was also preferentially
enriched in the synaptosome enriched fraction. These markers were also detected in
the nuclear fraction (P1), and in the crude plasmatic membrane fraction (P2), although
their signals were significantly lower than in synaptosomes. On the other hand, the sig-
nals for non-synaptic markers were faint or undetectable in synaptosomes, indicating
the low contamination of this fraction with non-synaptic membranes. Specifically, the
immunoreactivity for the nuclear marker histone H3 and the glial fibrillary acid protein
(GFAP) was highest in the nucleus-enriched fraction (P1), whereas the cytosolic marker
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glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was enriched in the cytoplasm
fraction (S1) (Supplementary Figure S1). We also examined the synaptosomes by dou-
ble immunofluorescence and high-resolution microscopy, combining MAP2/GFAP or
SNAP25/GFAP double immunofluorescence labelling with the membrane staining dye
DiIC16 and high-resolution fluorescence microscopy analysis (Supplementary Figure S2).
The DiIC16 dye allowed us to quantify the size and the origin of all particles found in the
preparation. Immunofluorescence assays showed that about 80% of particles displayed a
size between 0.25–1.5 µm, which is consistent with that described for synaptosomes. On the
other hand, 15% and 5% of the particles showed a size less than 0.25 µm and greater than
1.5 µm, respectively. Half of the DiIC16 positive particles within 0.25–1.5 µm range size
were identified as of neuronal origin by MAP2 and SNAP25 staining, whereas a very low
glial contamination was observed by GFAP-immunostaining. SNAP25 and MAP2 labelling
also revealed that about half of the particles in the synaptosome-enriched fraction were
composed of presynaptic or postsynaptic elements. These values are in good agreement
with other published data showing that isolated nerve terminals made up approximately
50% of the structures revealed by electron microscopy [14]. These results demonstrated the
suitability of the efficiency protocol used to purify mouse brain synaptosomes.
2.2. Characteristics of the Immunoreactive Signals Provided by Anti-CB1 Antibodies in Frontal
Cortical Synaptosomes Derived from Wild Type Mice
To study the CB1 receptor protein located in the synaptosomal fraction by Western
blot assays, we used three commercially available antibodies (CB1-Immunogenes, CB1-
Go-Af450 and CB1-Rb-Af380) that were raised against the 31 amino acids of the extreme
carboxy-terminus of the mouse CB1 receptor. These have been recently shown to be
the most reliable ones for Western blot [15]. As negative control, we used brain cortical
tissue of CB1-deficient mice (CB1-KO) to test the specificity of these antibodies for the
CB1 receptor. All three antibodies recognized a specific band at ~50 kDa consistent with
the 52 kDa theoretical molecular mass of the mouse CB1 receptor, which was absent
in synaptosomes derived from the cortical tissue of CB1-KO (Figure 1A). Furthermore,
the CB1-Immunogenes and the CB1-Go-Af450 antibodies clearly recognized a specific
extra band at ~35 kDa, which was also absent in synaptosomes obtained from CB1-KO
(Figure 1A). Strikingly, the lower molecular weight band was hardly detectable with the
CB1-Rb-Af380 antibody in most experiments (Figure 1A). To analyse whether the migration
of the observed ~50 kDa and ~35 kDa bands could be modified by proteolytic degradation
of the CB1 receptor, we performed Western blot assays of synaptosome samples subjected
to a potentially proteolytic condition by their incubation at 37 ◦C in the absence and the
presence of protease inhibitors. No changes were observed in the immunoreactivity of the
~50 kDa and ~35 kDa bands after incubation of synaptosomes at 37 ◦C for 1 or 2 h in the
absence or in the presence of protease inhibitors (Supplementary Figure S3A). Moreover,
no changes were observed when the synaptosomal enriched fraction was obtained in the
absence or the presence of protease inhibitors during the fractionation procedure (see
Supplementary Table S2). These results suggest that under our experimental conditions,
the appearance of the lower molecular mass band of ~35 kDa is not the product of the
proteolytic degradation of the ~50 kDa band protein, at least during the fractionation
procedure or handling and processing synaptosomes.
As the CB1 receptor has two consensus sequences for N-linked glycosylation at the
N-terminal tail, we examined whether the two immunoreactive bands detected in Western
blot assay could be glycosylated and non-glycosylated forms of the receptor. To answer this
question, the frontal cortical synaptosomes were treated with the peptide N-glycosylase
enzyme (PNGase F). PNGase F is the most effective enzymatic method for removing almost
all N-linked oligosaccharides from glycoproteins, because it cleaves between the innermost
GlcNAc and asparagine residues of high mannose, hybrid, and complex oligosaccharides.
As recommended by the manufacturer, we performed Western blot assays to analyse the
migration profile of the CB1 receptor bands obtained with each one of the three antibodies
after incubating synaptosomes for one hour at 37 ◦C with the PNGase F enzyme (25 UI/µg
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total synaptosomal protein). N-glycosidase treatment of synaptosomes resulted in a clear
shift in the migration profile of the ~50 kDa band, which was not present anymore for
any of the three antibodies used. Instead, two new specific bands migrating at ~40 kDa
and ~37 kDa were detected with all three antibodies (Figure 1B; Supplementary Figure
S3B,C). However, no changes in the intensity of the ~35 kDa band were observed when
the CB1-Go-450 or the CB1-Immunogenes antibody was used. Strikingly, the CB1-Rb-
Af380 antibody, which hardly detected the ~35 kDa band in untreated samples, recognized
a stronger ~35 kDa band in the PNGase F treated synaptosomes (Figure 1B). However,
this band was unspecific because it was also detected in cortical synaptosomes of the
CB1-KO mice (Supplementary Figure S3C). The possibility that the ~40 kDa and ~37 kDa
immunoreactive band could be products of a partial deglycosylation of the CB1 receptor
was tested by doubling both the PNGase amount and incubation time, but no changes












Figure 1. Immunoblot against CB1 receptor protein using CB1-Immunogenes, CB1-Go-Af450 and
CB1-Rb-Af380 antibodies. (A) Representative Western blots carried out loading the same amount
of total protein (20 µg/lane) from synaptosomes of brain cortical tissue of wild-type (WT) and
CB1-KO mice. The molecular weights depicted correspond to the signal of the standard markers.
(B) Representative Western blots carried out loading the same amount of control and PNGase F
treated frontal cortical synaptosomes (20 µg total protein/lane). The approximate molecular masses
of the immunoreactive species detected on the blot are indicated.
2.3. Subsynaptic Compartmentalization of the CB1 Receptor and Other Proteins of the
Endocannabinoid System in Frontal Cortex Synaptosomes Derived from Wild-Type and
CB1-RS Mice
To investigate the synaptic distribution of CB1 receptor and other proteins of the
endocannabinoid system, cortical synaptosomes were fractionated in three major subsy-
naptic domains: the presynaptic active zone (PAZ), the postsynaptic density (PSD), and
the extra-synaptic zone (EXTRA). The extra-synaptic region consists of plasma membrane
not specialized in synapses and of cytoplasm of synaptic terminal, whereas the presy-
naptic active zone and the postsynaptic density consist of “particle web” components
and protein dense specialization attached to the presynaptic and postsynaptic membrane,
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respectively [11]. We recovered 67%, 12%, and 5% of the total amount of synaptosomal
membrane protein in the EXTRA, PSD, and PAZ fractions, respectively. Thus, proteins
from the extra-synaptic region contribute in the largest proportion to the synaptosomal frac-
tion. The efficiency of the protocol was validated by Western blot assays. Equal amounts
of total protein of the three isolated subsynaptic fractions (PAZ, PSD, and EXTRA), and
increasing amounts of total protein of the initial synaptosomal fraction were loaded on the
same gel. We used antibodies raised against PSD-95, Shank3, and gephyrin as markers
of PSD, and Munc-18 and SNAP-25 as markers of PAZ and EXTRA subsynaptic domains.
As expected, the immunoreactivity of PSD-95, Shank3, and gephyrin was only detected
in the PSD fraction, and the intensity of the signal was significantly higher than in the
synaptosome fraction, which is in line with the fact that the PSD fraction was purified
approximately eight times compared to synaptosomes, considering the protein yield of
each subsynaptic fraction (Supplementary Figure S4). On the other hand, the presynaptic
proteins Munc-18 and SNAP-25 were detected in PAZ and EXTRA fractions, although
they showed higher enrichment in the EXTRA fraction than in the PAZ (Supplementary
Figure S4). The functional profile of these two proteins is consistent with what might be
expected because they reflect synaptic and non-synaptic populations of proteins found in
the synaptic terminal. These results showed that our protocol is adequate for obtaining
subsynaptic domains from synaptosomes.
Once the efficiency of the protocol was established, we analysed the subsynaptic
compartmentalization of the CB1 receptor using the three antibodies described above:
CB1-Immunogenes, CB1-Go-Af450, and CB1-Rb-Af380. With respect to the ~50 kDa band,
the immunoreactivity was highest in the EXTRA fraction, although a clearly detectable but
considerably less intense signal was detected in the PSD fraction (Figure 2A). Furthermore,
a weak band was detected in the PAZ fraction. Relative to the total receptor signal detected
in EXTRA and PSD compartments, 68% and 32% of the immunoreactivity was present in
each of the domains, respectively, with no differences between the results obtained with the
three antibodies (Figure 2C). In summary, the density of the CB1 receptor (~50 kDa band)
in the extra-synaptic membrane was considerably higher than in the postsynaptic domain.
Densitometric analysis of the ~35 kDa immunoreactive bands showed similar values in
the EXTRA and PSD fractions, indicating that the ~50 kDa and ~35 kDa proteins partition
differently (Figure 2C). Although the same amount of total protein from these fractions
was loaded for Western blot analysis, the yield of total synaptosome protein in the EXTRA
fraction was almost 5.8-fold higher than in the PSD fraction, revealing that most CB1 recep-
tor is located in the extra-synaptic membrane (about 90% of the total amount of synaptic
immunoreactivity). Therefore, the immunoreactive signal detected in synaptosomes is
mainly derived from the EXTRA fraction and the contribution of the CB1 receptor signal of
the PSD (about 8%) and the PAZ (about 1%) is very low. Altogether, the distribution of CB1
receptor in the frontal cortex is similar to rat striatal CB1 receptor, which was found in all
subsynaptic fractions [12]. Regarding the Gαi/o proteins, the canonical transducers cou-
pled to CB1 receptor at the plasma membrane, three of the four αi/o subunits studied (Gαo,
Gαi1, and Gαi3) were found exclusively in the EXTRA fraction (Figure 2A). Interestingly,
Gαi2 was mostly detected in the PSD fraction, although a weak signal could be observed in
the EXTRA fraction. Like the Gαo, Gαi1, and Gαi3 proteins, the CB1 receptor interacting
protein-1a (CRIP1a) was only detected in the EXTRA fraction. The proteins involved in the
synthesis and degradation of the major endocannabinoid 2-arachidonylglycerol (2-AG),
Gαq/11 subunit, phospholipase C-β1 (PLC-β1) and monoacylglycerol lipase (MAGL)
were found in the EXTRA fraction, whereas diacylglycerol lipase-α (DAGL-α) was mostly
enriched in the PSD fraction (Figure 2B). Finally, the Gβ subunit signal was highest in the
EXTRA fraction, but also clearly detectable in the PAZ and, to a lesser extent, in the PSD
fraction (Figure 2A). These results are consistent with the synaptic retrograde signalling
function assigned to 2-AG.












 Figure 2. Subsynaptic compartmentalization of the CB1 receptor, the canonical transducers coupled to CB1 receptors and
other proteins of the endocannabinoid system in PAZ, PSD, and EXTRA fractions isolated from cortical synaptosomes
derived from wild-type mice. Representative Western blots carried out by immunoblotting increasing amounts of cortical
synaptosomes (3, 6, 9, and 12 µg/lane) and different subsynaptic fractions of wild-type mice (3 µg/lane) using antibodies
against CB1 receptor, Gαi/o subtypes, Gβ and Crip1a (A) and Gαq/11, PLC-β1, DAGL-α, and MAGL (B). Presynaptic
fraction PAZ, postsynaptic fraction PSD, and extrasynaptic fraction EXTRA. Protein migration was consistent with their
expected molecular mass. For the CB1 receptor and the Gαi2 protein, extra bands migrating at ~35 kDa and ~36 kDa
were detected, respectively (CB1, 52.8 kDa; Gαo 40.1 kDa; Gαi1, 40.5 kDa; Gαi2, 40.4 kDa; Gαi3, 40.5 kDa; Gβ (common),
37.3 kDa and 36.3 kDa 1 and 2 isoforms; CRIP1a, 18.6 kDa; Gαq/11, 42.0 kDa; PLC-β1, 138.3 kDa and 133.3 kDa, the β1a
and β1b isoforms, respectively; DAGL-α, 115.3 kDa; MAGL, 33.3 kDa). The molecular weights depicted correspond to the
signal of the standard markers. (C) The bar graphs show the subsynaptic distribution of the CB1 receptor immunoreactive
signals of ~50 kDa and ~35 kDa bands obtained with the CB1-Immunogenes, CB1-Go-Af450 and CB1-Rb-Af380 antibodies.
The quantification was performed using data from the three antibodies together. The immunoreactive signals of PSD and
EXTRA fractions are shown normalized to the total signal detected in both compartments. ~50 kDa: EXTRA 67.9 ± 0.7 vs.
PSD 32.0 ± 0.7; ~35 kDa: EXTRA 52.8 ± 3.9 vs. PSD 47.9 ± 4.8. Values correspond to the means ± SEM of five independent
assays, using subsynaptic fraction preparations obtained from a pool of cerebral cortices of eight adult mice. Unpaired two
tailed t test. *** = p < 0.001.
Then, we examined the subsynaptic distribution of the CB1 receptor in synapto-
somes derived from frontal cortex of CB1-RS mice. The subsynaptic marker distribution
was qualitatively indistinguishable between the wild-type and CB1-RS (Supplementary
Figures S4 and S5). Semiquantitative analysis of the CB1-immunoreactive bands showed
no statistically significant differences between wild-type and CB1-RS mice (Supplementary
Table S3). In other words, the ~50 kDa and ~35 kDa bands detected by the three anti-CB1
antibodies were equally distributed in wild-type and in CB1-RS mice (Figure 2A,C; Sup-
plementary Figure S6A,C). We also studied the subsynaptic distribution of proteins of the
endocannabinoid system in CB1-RS mice. The subsynaptic profile of different elements
of the endocannabinoid system and the signalling proteins coupled to CB1 receptor was
qualitatively similar between wild-type and CB1-RS mice (Figure 2B and Supplementary
Figure S6B).
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2.4. Localization of CB1 Receptors in Lipid Raft and Non-Lipid Raft Microdomains of
Synaptosomal Plasma Membranes Obtained from Frontal Cortical Brain Tissue of Wild-Type and
CB1-RS Mice
We further examined the localization of the CB1 receptor in “raft” and “non-raft”
microdomains derived from the synaptosomal plasma membranes of the frontal cortex of
wild-type and CB1-RS mice. Typically, a total of 12 fractions of increasing sucrose density
were obtained and were biochemically characterized by quantitative analysis of alkaline
phosphatase enzymatic activity, determination of the total protein amount, and the use
of raft and non-raft markers (Figure 3; Supplementary Figure S7). Low protein content
and high alkaline phosphatase activity are characteristic of lipid raft fractions. In the
Western blot assays, we used antibodies raised against thymocyte-1 (Thy-1) and flotillin
proteins, and Na+/K+-ATPase protein as markers of raft and non-raft microdomains,
respectively. In the wild type mice, alkaline phosphatase activity was highest in fractions
four and five along with a low protein content (Figure 3B,C). We also detected increased
immunoreactivity for raft markers and decreased or absent immunoreactivity for non-raft
markers in these two fractions, suggesting that they were enriched in raft microdomains
(Figure 3A). Specifically, the immunoreactivity of Thy-1 was only detected in fractions four
and five and the highest intensity signal of flotillin was also detected in these two fractions,
with a tendency to weaken in higher density fractions. Furthermore, it should be noted that
the amount of total protein loading of the fractions four and five was lower compared to the
others because the same volumes of fractions were loaded in these Western blot assays. On
the other hand, the fractions between 8 and 12 displayed no alkaline phosphatase activity,
high protein concentration, and high and low immunoreactivity for Na+/K+-ATPase and
flotillin, respectively (Figure 3A–C). With these results, we concluded that fractions four and
five were enriched in raft microdomains and fractions 6 to 12, on the other hand, were non-
raft fractions. Subsequently, the expression of CB1 receptor and Gαi/o protein subtypes
was analysed (Figure 3A). Unexpectedly, CB1 immunoreactivity distribution profile varied
depending on the antibody used. Whereas CB1-Rb-Af380 antibody recognized a single
specific band at ~50 kDa exclusively in the raft fraction, the CB1-Immunogenes antibody
recognized ~50 kDa and ~35 kDa specific bands in both raft and non-raft fractions. On the
other hand, the CB1-Go-Af450 antibody did not detect any CB1 receptor signal in any of
the raft and non-raft fractions. Different levels of Gαi/o protein subtypes were detected in
both raft and non-raft fractions, suggesting that the CB1 receptor can interact with different
Gαi/o subtypes in both compartments.
In the CB1-RS mice, alkaline phosphatase activity was highest in fractions five and
six along with a stronger immunoreactivity for lipid raft markers, and lower or absent for
non-raft markers, suggesting that these fractions were enriched in raft microdomains (Sup-
plementary Figure S7A–C). On the other hand, the fractions between 8 and 12 displayed no
alkaline phosphatase activity, high protein concentration, and high and low immunoreac-
tivity for non-raft and raft markers, respectively (Supplementary Figure S7A–C). The raft vs
non-raft partitioning of the CB1 receptor did not differ qualitatively between wild-type and
CB1-RS mice with both CB1-immunogenes and CB1-Rb-Af380 anti-CB1 antibodies. The
raft vs. non-raft partitioning profile of the α subunits of the Gαi/o protein family analysed
was also similar in wild-type and CB1-RS mice (Figure 3A; Supplementary Figure S7A).
2.5. Analysis of the Coupling of the CB1 Receptor to Gαi/o Proteins in Frontal Cortical and
Hippocampal Synaptosomes Obtained from CB1-RS and Wild-Type Brain Mice
The relative expression of the CB1 receptor in wild-type and CB1-RS mice was anal-
ysed in frontal cortex and hippocampal synaptosomes using CB1-Immunogenes, given that
this antibody recognizes the CB1 receptor located in both raft and non-raft compartments
derived from synaptosomal membranes. The expression of CB1 receptor was higher in
hippocampal synaptosomes than in frontal cortical synaptosomes in both wild-type and
CB1-RS mice. With respect to the immunoreactivity of the ~50 kDa band, no statistical
differences were observed either in hippocampal or in frontal cortical synaptosomes (Sup-
plementary Figure S8 and Table S4). We did not observe statistically significant difference in
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the immunoreactive signals of the ~35 kDa band in frontal cortical synaptosomes. However,
in hippocampal synaptosomes, the immunoreactivity of the ~35 kDa band was 25% lower
in CB1-RS mice than in wild-type mice (Supplementary Figure S8 and Table S4). Finally,
synaptosomes from CB1-RS mice were characterized for canonical functionality of the CB1
receptor, and results were compared with synaptosomes obtained from wild-type mice.
For this purpose, we performed [35S]GTPγS binding assays stimulated by the cannabinoid
agonist CP 55,940 in synaptosomes purified from frontal cortex and hippocampus (Sup-
plementary Figure S9). The analysis of the CP 55,940 concentration–response curves for
stimulation of the specific [35S]GTPγS binding provided the same maximal percent stimu-
lation (%Emax) and pEC50 values both in frontal cortical and hippocampal synaptosomes
from wild-type and CB1-RS mice (Supplementary Table S5).
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with their expected molecular mass. For the CB1 receptor and the Gαi2 protein, an extra band migrating at ~35 kDa
and ~36 kDa was detected, respectively. Na+/K+-ATPase, 112.3 kDa; Flotillin, 47.5 kDa; thymocyte 1 (Thy-1), 18.1 kDa;
CB1 receptor, 52.8 kDa; Gαo 40.1 kDa; Gαi1, 40.5 kDa; Gαi2, 40.4 kDa; Gαi3, 40.5 kDa. The molecular weights depicted
correspond to the signal of the standard markers. (B) Total protein content of the collected 12 fractions and of the pellet (P).
(C) Alkaline phosphatase activity of the collected 12 fractions and of the pellet (P).
2.6. Analysis of the CB1 Receptor Protein Expression and Gαi/o Protein Coupling in
Synaptosomes Obtained from Frontal Cortical and Hippocampal Tissue of Glu-CB1-RS,
GABA-CB1-RS and CB1-RS Mice
Once the CB1-RS ouse model was validated, the expression and functional coupling
of the CB1 receptor was analysed in brain synaptosomal me branes from Glu-CB1-RS
and GABA-CB1-RS ice. Increasing amount of total protein of CB1-RS, Glu-CB1-RS, and
GABA-CB1-RS frontal cortical synaptosomes were resolved by SDS-PAGE and CB1 re-
ceptor expression was analysed by immunoblot using the CB1-Immunogenes antibody
(Figure 4A). Anti-syntaxin antibody was used as a protein loading control. A semiquanti-
tative analysis of immunoreactive signals was performed comparing slopes values, which
were obtained by regression analysis of curves that were generated plotting OD values for
each protein loading (Figure 4B). Regression analysis of standard curves revealed a linear
relationship (r2 = 0.98) between the amount of protein and the relative optical density for
each sample (see legend to Figure 4). The immunoreactivity for the CB1 receptor ~50 kDa
band was similar in synaptosomal fractions fro Glu-CB1-RS and GABA-CB1-RS, reaching
in b th partial rescue mice about 45% of the signal found in CB1-RS, with no statistical
difference between Glu-CB1-RS and GABA-CB1-RS (Supplem ntary T ble S6). The same
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relative pattern was observed for the ~35 kDa band. Furthermore, the immunoreactivity
level in these two types of neurons reached around 85% of the CB1 signal seen in CB1-
RS samples, indicating that in the frontal cortical synaptic terminals the CB1 receptor is
expressed dominantly in these two types of neurons. As in the frontal cortex, a semiquanti-
tative analysis of immunoreactive signals in hippocampal synaptosomes was performed
comparing slopes values (Figure 4C,D). Levels of 28% and 70% of the immunoreactivity of
the ~50 kDa band found in CB1-RS were present in the Glu-CB1-RS and GABA-CB1-RS
mice, respectively (Supplementary Table S6). As expected, the slope values in synapto-
somal samples from either partial rescue mice were significantly lower than in CB1-RS
samples. The same relative pattern was observed for the ~35 kDa band. Furthermore, the
synaptosomal immunoreactivity level in these two neuronal types reached around 100% of
the total signal of the CB1 receptor, indicating that in the hippocampal synaptic terminals
the CB1 receptor is expressed almost exclusively in GABAergic and glutamatergic neurons.
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Figure 4. CB1 receptor protein levels in synaptoso es obtained from frontal cortical and hippocampal tissue of Glu-CB1-RS,
GABA-CB1-RS, and CB1-RS mice. Representative Western blots carried out by immunoblotting increasing amounts of
frontal cortical (A) and hippocampal (C) synaptosomes (6, 9 or 12 µg/line). CB1-Immunogenes antibody was used for
detecting CB1 receptor protein, and anti-syntaxin antibody was used as a loading control. The molecular weights depicted
correspond to the signal of the standard markers. (B). Regression analysis of curves generated by optical density (OD)
values of the immunoreactive signals of CB1 receptor from frontal cortical synaptosome membranes. ~50 kDa: CB1-RS:
y = 9.64x − 16.34, r2 = 0.99. Glu-CB1-RS: y = 4.39x − 3.08, r2 = 0.99. GABA-CB1-RS: y = 4.41x − 1.81, r2 = 0.99. ~35 kDa:
CB1-RS: y = 6.79x − 22.23, r2 = 0.98. Glu-CB1-RS: y = 3.33x − 8.41, r2 = 0.99. GABA-CB1-RS: y = 2.88x − 5.20, r2 = 0.99.
(D). Regression analysis of curves generated by optical density (OD) values of the immunoreactive signals of CB1 receptor
from hippocampal synaptosome membranes. ~50 kDa: CB1-RS: y = 10.52x − 26.04; r2 = 0.99; Glu-CB1-RS: y = 2.97x − 5.87;
r2 = 0.99. GABA-CB1-RS: y = 7.48x − 22.97, r2 = 0.99. ~35 kDa: CB1-RS: y = 11.13x − 36.19; r2 = 0.99. Glu-CB1-RS:
y = 3.72x − 12.54; r2 = 0.99. GABA-CB1-RS: y = 6.97x − 26.17; r2 = 0.99. Analysis of the CB1 receptor protein expression by
the slope comparison method in frontal cortical an in hippocampal synaptosomes is shown in the Supplementary Table S6.
The functional coupling of the CB1 receptor was then assessed in synaptosomal
membranes obtained from frontal cortex of CB1-RS, Glu-CB1-RS, and GABA-CB1-RS mice
by CP 55,940- and WIN 55,212-2-stimulated specific [35S]GTPγS binding. Similar values
of %Emax and pEC50 parameters were obtained in Glu-CB1-RS and GABA-CB1-RS mice,
with no significant differences between them (Figure 5A,B; Table 1). The %Emax values
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in synaptosomal samples from either partial rescue mice were significantly lower than
in CB1-RS samples, whereas no differences were observed in the pEC50 values (Table 1).
As expected, no cannabinoid agonist-stimulated [35S]GTPγS binding was observed in
Stop-CB1 mice (Figure 5A,B). Next, we assessed the functional coupling of the CB1 receptor
in synaptosomes obtained from hippocampus of Glu-CB1-RS and GABA-CB1-RS mice by
CP 55,940 and WIN 55,212-2-stimulated specific [35S]GTPγS binding (Figure 5C,D). The
%Emax value in synaptosomal samples from Glu-CB1-RS rescue mice was significantly
lower than in CB1-RS synaptosomes, whereas no differences were observed between
GABA-CB1-RS and CB1-RS synaptosomes (Table 1). The %Emax values differed between
synaptosomal fractions from partial rescue mice, reaching a statistical significance when
CP 55,940 agonist was used in the assay. In contrast, no significant difference (Figure 5C,D;
Table 1) was obtained between partial rescue mice %Emax with WIN 55,212-2, although
the value of the Glu-CB1-RS mouse was 40% lower than of GABA-CB1-RS. Similar values
of pEC50 parameters were obtained in all three genotypes, with no significant differences
(Table 1). Again, no cannabinoid agonist-stimulated [35S]GTPγS binding was observed in
synaptosomes of Stop-CB1 mice (Figure 5C,D).











Figure 5. CB1 receptor coupling to Gαi/o proteins in synaptosomes obtained from frontal cortical and hippocampal
tissue of Glu-CB1-RS, GABA-CB1-RS, CB1-RS, and Stop-CB1 mice. CP 55,940- (A) and WIN 55,212-2- (B) stimulated
[35S]GTPγS binding in frontal cortical synaptosomes. CP 55,940- (C) and WIN 55,212-2- (D) stimulated [35S]GTPγS binding
in hippocampal synaptosomes. Concentration–response curves were constructed using mean values ± SEM from triplicate
data points of three independent experiments. Emax values are expressed as % specific [35S]GTPγS bound of basal.
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Table 1. Concentration–response curves for agonist-stimulated specific [35S]GTPγS binding in frontal
cortical and hippocampal synaptosomes derived from CB1-RS, Glu-CB1-RS, and GABA-CB1-RS
mice. Values correspond to the means ± SEM of three independent experiments. Both in frontal
cortex and hippocampus the experiments were carried out using two preparations enriched in
synaptosomes, each of them obtained from pools of the frontal cortices and hippocampi of eight




%Emax 211.7 ± 2.37 157.11 ± 1.79 * 159.00 ± 1.10 *
pEC50 6.85 ± 0.07 6.77 ± 0.12 6.72 ± 0.12
WIN 55,221-2
%Emax 248.0 ± 18.74 189.55 ± 12.17 * 184.8 ± 6.39 *
pEC50 6.75 ± 0.11 6.14 ± 0.12 6.13 ± 0.04
Hippocampus
CP 55,940
%Emax 248.60 ± 16.36 183.43 ± 14.4 * 240.60 ± 10.67 #
pEC50 6.61 ± 0.09 6.59 ± 0.16 6.61 ± 0.09
WIN 55,221-2
%Emax 270.90 ± 9.68 195.85 ± 5.44 * 258.1 ± 12.70
pEC50 6.11 ± 0.12 5.93 ± 0.13 6.02 ± 0.12
Basal (cpm) 28,040 ± 2102 23,344 ± 1767 * 23,559 ± 1725 *
* = significantly different from CB1-RS, p < 0.05; # = significantly different from Glu-CB1-RS, p < 0.05.
2.7. Analysis of the CB1 Receptor Coupling to Gαi/o Proteins in Control and MβCD Pretreated
Synaptosomes Obtained from Frontal Cortical Tissue of Glu-CB1-RS, GABA-CB1-RS, and
CB1-RS Mice
We also assessed whether cholesterol exerted its negative regulation on agonist efficacy
differently on CB1 receptor in glutamatergic or GABAergic terminals. To this end, we
first determined the concentration of methyl-β-cyclodextrin (MβCD) necessary to observe
an increase in the maximal responses to full efficacy cannabinoid agonists in [35S]GTPγS
binding assays. Thus, first, we analysed the effect of the pretreatment of synaptosomal
membranes with MβCD (5 mM, 10 mM, and 20 mM) on CP 55,940-stimulated [35S]GTPγS
binding at a maximal concentration of the agonist (10 µM). The results showed an increase
in the efficacy in comparison to the control (vehicle pretreated synaptosomal membranes) at
10 mM and 20 mM MβCD (Supplementary Figure S10; Supplementary Table S7). Because
the maximal increase in efficacy with respect to control was achieved with 10 mM MβCD,
this concentration was used for subsequent experiments. CP 55,940- and WIN 55,212-
2-stimulated [35S]GTPγS binding assays were performed in control and MβCD-treated
frontal cortical synaptosomes from Glu-CB1-RS and GABA-CB1-RS mice. The cholesterol
depletion (30% decrease in plasma membrane levels) by MβCD (10 mM) increased the
maximal CP 55,940- and WIN 55,212-2-stimulated [35S]GTPγS specific binding, and the
magnitude of this effect was not affected by the genotype (Figure 6A,B; Supplementary
Table S8). Next, we generated concentration–response curves for CP 55,940-stimulated
[35S]GTPγS binding to determine whether cholesterol depletion also impacted the agonist
potency (pEC50 parameter). No statistically significant changes were observed for this
parameter between MβCD treated and control synaptosomes in Glu-CB1-RS and GABA-
CB1-RS mice (Figure 6C,D; Table 2). Again, the increase in the efficacy of CP 55,940 agonist
induced by MβCD treatment did not differ statistically between CB1 receptor in excitatory
or inhibitory terminals (Figure 6C,D; Table 2).






Figure 6. CB1 receptor coupling to Gαi/o proteins in control and 10 mM MβCD pretreated synaptosomes from frontal
cortical tissue of Glu-CB1-RS and GABA-CB1-RS mice. (A,B) Bar graph of 10 µM CP 55,940 and 10 µM WIN 55,212-2-
stimulated maximal [35S]GTPγS binding. (C,D) Concentration–response curves for the CP 55,940-stimulated [35S]GTPγS
binding. Concentration–response curves were constructed using mean values ± SEM from triplicate data points of three
independent experiments. Emax values are expressed as % specific [35S]GTPγS bound of basal.
Table 2. Concentration–response curves for the CP 55,940-stimulated specific [35S]GTPγS binding
in vehicle (control) or MβCD pretreated frontal cortical synaptosomes derived from Glu-CB1-RS
and GABA-CB1-RS mice. Values correspond to the means ± SEM of three independent experiments
performed in triplicate, using synaptosomes enriched preparations obtained from a pool of the frontal
cortices of eight adult mice. Unpaired (%Emax) or paired (pEC50, Basal) two-tailed t-test.
Glu-CB1-RS GABA-CB1-RS
Control MβCD Control MβCD
%Emax 170.95 ± 3.23 225.87 ± 8.75 * 167.43 ± 9.17 217 ± 14.20 *
pEC50 6.61 ± 0.12 6.78 ± 0.06 7.02 ± 0.08 6.96 ± 0.13
Basal (cpm) 11,175 ± 264 7443 ± 267 * 10,324 ± 457 8696 ± 95
* = significantly different from control, p < 0.05.
3. Discussion
To gain insight into the organizational principles of plasma membrane location and
Gαi/o protein signalling of the CB1 receptor at glutamatergic and GABAergic terminals of
the mouse frontal cortex and hippocampus, the use of a highly specific anti-CB1 receptor
antibody is mandatory. Although many antibodies designed against distinct antigenic
sequences of the CB1 receptor have been developed, the interpretation of results has been
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controversial, at times providing poorly reproducible data. Therefore, proper antibody
testing and validation must be considered when studies using anti-CB1 antibodies are
conducted. In this sense, we have recently provided robust data on the suitability for
different applications of several anti-CB1 antibodies [15], highlighting the need for the
fit-for-purpose (F4P) approach for validation of antibodies and the importance of choosing
the platform that best fits their end-use. In this previous work, the CB1-Rb-Af380 and
CB1-Go-Af450 antibodies, both raised against the carboxy-terminal 31 amino acids of the
mouse CB1 receptor, provided excellent results for the recognition of the denatured CB1
receptor from brain tissue in Western blot assay. Hence, in the present study, we used the
commercial CB1-Rb-Af380, CB1-Go-Af450, and CB1-Immunogenes antibodies (all of them
raised against an identical antigenic sequence) for the immunodetection of the CB1 receptor
at synaptic terminals of the frontal cortical and hippocampal mouse brain tissue. All three
antibodies recognized a specific band at ~50 kDa consistent with the 52 kDa predicted
molecular mass of mouse CB1 receptor. Additionally, a specific extra band at ~35 kDa was
clearly recognized with CB1-Immunogenes and CB1-Go-Af450 antibodies, whereas it was
hardly detectable with the CB1-Rb-Af380 antibody in most experiments. The specificity
of the detected signals was validated using cortical synaptosomes from CB1-KO animals
(see Figure 1A). The molecular weight of the ~50 kDa-specific band detected by Western
blot agrees with previous results where CB1-Rb-Af380 and CB1-Go-Af450 antibodies have
been used [14,16,17], including some from our laboratory [5,10,15,18,19]. However, the
second less intense but clearly positive ~35 kDa band detected here was not previously
reported in mice. The discrepancy could be partly explained by the different subcellular
fractions and/or experimental conditions used between the studies, which could impact
the sensitivity of the antibodies for the detection of this CB1 receptor species. Although
detection of unexpected bands at low molecular weight can be indicative of proteolytic
degradation, we did not observe changes in the immunoreactivity of the ~50 kDa and
~35 kDa bands by the preincubation of synaptosomal membranes at 37 ◦C or the inclusion
of protease inhibitors. Previous results from our laboratory and other authors have reported
that the gel migration of the CB1 receptor can be altered by modifying its N-glycosylation
status [20–23]. Given that the extracellular N-terminus of the mouse CB1 receptor has
two consensus sequences for N-linked glycosylation [24], we examined the effects of
the pretreatment of cortical synaptosomes with PNGase F. This enzymatic pretreatment
resulted in a clear shift in the migration profile of the ~50 kDa immunoreactivity band,
rendering it virtually undetectable with any of the three antibodies used. This observation
agrees with some previous reports [22,23] and it indicates that the ~50 kDa band represents
an N-glycosylated species of the CB1 receptor. At the same time, other studies reported a
detection of a major band of about 60 kDa using different anti-CB1 antibodies [20,21,25–28],
and although it has been explained as a result of glycosylation of the CB1 receptor, the
discrepancies between these reports and the one presented here must be due to other
factors. In the PNGase F pretreated samples, we detected new CB1 receptor-specific bands
migrating at ~40 kDa and ~37 kDa, although we were not able to observe an increase in
the ~35 kDa signal. In addition, the CB1-Rb-Af380 antibody recognized a new unspecific
strong signal at ~35 kDa (see Figure 1B). Probably, this signal corresponds to the cross-
reactivity of the CB1-Rb-Af380 antibody with the 35 kDa PNGase F from Flavobacterium
meningosepticum [29,30], which was present in abundance in the pretreated synaptosomal
sample. The emergence of CB1-specific immunoreactive proteins with different apparent
molecular masses on SDS-PAGE after its deglycosylation could be explained, at least in part,
by the formation of a tandem electrophoretic mobility shift (EMS-shift) motif within the
sequence of the N-terminus of the CB1 receptor as a consequence of PNGase F-mediated
deamination of asparagine residues. Recently, it has been reported that the mobility
shift often observed in post-translationally phosphorylated proteins (phosphorylation-
dependent electrophoretic mobility shift; PDMES), rather than by the molecular mass
of covalently linked phosphate groups, is caused by the presence of negatively charged
amino acids around the phosphorylation site that generate an electrophoretic mobility
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shift (EMS)-related motif θX1-3θX1-3θ, where θ corresponds to an acidic or phosphorylated
amino acid and X represents any amino acid [31]. As these authors proposed, EMS-motifs
inhibit the binding of SDS to the peptide bond of proteins by charge–charge repulsion
(see Supplementary Figure S11A,B), which results in a decreased ratio of SDS/peptide
stoichiometry causing a mobility shift. It is likely that generation of a tandem EMS-
motif in the sequence of the canonical mouse CB1 receptor following PNGase F-catalysed
deamination of Asn-78 and Asn-84 (see Supplementary Figure S11C) could be sufficient
to cause a mobility shift of about 5 kDa, which could also account for greater apparent
molecular mass of deglycosylated species than the non-glycosylated one (~35 kDa).
To fully investigate the synaptic distribution of the CB1 receptor, mouse cortical synap-
tosomes from wild-type and CB1-RS mice were subjected to a fractionation protocol based
on the differential pH and detergent sensitivity of three major subsynaptic domains [11]:
the presynaptic fraction PAZ, the postsynaptic fraction PSD and the extrasynaptic fraction
EXTRA. In agreement with previously reported electron microscopy data [32], our data
revealed that the CB1 receptors are primarily located in the extrasynaptic membrane of
the terminals together with the Gαi/o subunits involved in its canonical downstream
signalling and with CRIP1a, a protein that interacts with the CB1 receptor to modulate its
functional state [33,34]. A smaller but clearly detectable pool of CB1 receptor was located
in the PSD fraction, which is consistent with some previous reports [12,35]. In some experi-
ments, a very weak signal close to the detection limit was observed in the PAZ fraction.
This is also consistent with immunogold electron microscopy because the CB1 receptor
can hardly be found inside the presynaptic active zone [32]. Based on the protein yield
for each subsynaptic fraction, it can be concluded that about 90% of the total CB1 receptor
expressed in cortical synaptosomes is found in the extrasynaptic fraction. The CB1 receptor
immunoreactivity, found extrasynaptically, which may indicate recycling and/or newly
synthesized pools of the CB1 receptors, is concordant with previous electron microscopy
findings in the hippocampus, where presynaptic CB1 receptor was found primarily in
extrasynaptic membranes of GABAergic boutons [36,37]. Of course, in the present study,
receptors in the extrasynaptic fraction may comprise postsynaptic receptors outside the
postsynaptic density as well, and we found CB1 receptor also in the postsynaptic density.
With respect to other proteins involved in the synthesis and degradation of the 2-AG,
the Gαq/11 subunits, PLC-β1, and MAGL were found in the EXTRA fraction, whereas
DAGL-α was mostly enriched in the postsynaptic density fraction. Although both PLC-β1
and DAGL-α are located around the postsynaptic dense zone at the edge of glutamatergic
synapses [38–42], DAGL-α contains binding motifs that allow it to interact with the post-
synaptic scaffold protein Homer [43], which could explain the immunoreactivity in the
PSD fraction.
In agreement with previous studies, our results indicate that several Gαi/o protein
subtypes coexist in the extrasynaptic region (EXTRA), while only the Gαi2 subtype was de-
tected in the postsynaptic density (PSD). One of the earliest discoveries in the cannabinoid
field has been the dependence of cannabinoid effects on pertussis toxin (PTX) sensitive
G proteins [44]. This was soon followed by more detailed studies showing the possible
involvement of the different Gi/o subtypes. Thus, Gαo and various Gαi subtypes were
co-immunoprecipitated with CB1 receptor from solubilized rat brain membranes [45]. In
PTX-treated rat primary neurons, expression of the PTX insensitive Go, Gi2, and Gi3, but
not Gi1 was able to rescue the decreased excitatory postsynaptic currents [46]. More re-
cently, specific activation of Gαi1, Gαi2, and Gαi3 but not Gαo protein subunits by CB1 was
shown using [35S]GTPγS scintillation proximity assay [47] in CB1-transfected HEK cells.
In the synaptic active zone ion channels predominate. GPCRs can mostly be found
at the extra- or perisynaptic areas where they are strategically located to sense spillover
of neurotransmitters and provide feedback. Nevertheless, GPCRs were also shown to be
present in the PSD [48,49] but corresponding studies showing which particular G protein
subtypes these receptors couple to in vivo are still missing. However, it is important to
note that our data demonstrates no functional coupling between CB1 and any specific G
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protein subtype. Considering their subsynaptic localization in our experiments we can
postulate that in the frontal cortex of mice perisynaptic CB1 receptors can signal through
Gi1, Gi3, or Go proteins or any combination of those.
Finally, we applied a protocol described by Ostrom and Insel (2006) [13] to characterize
the partition of the CB1 receptor and the Gαi/o subunits located in lipid and non-lipid rafts
microdomains of cortical synaptosomal membranes. Our data show that the CB1 receptor
is located both in lipid raft and non-lipid raft membrane compartments, with the possibility
of coupling to different Gαi/o subunits. Unexpectedly, the immunoreactivity profile of the
CB1 receptor differed using the CB1-Rb-Af380 and the CB1-Immunogenes antibodies. Thus,
CB1-Rb-Af380 antibody recognized the CB1 receptor exclusively in the lipid raft, whereas
the CB1-Immunogenes antibody recognized the receptor in both fractions, indicating that
the CB1-Rb-Af380 antibody recognizes only a partial pool of the total plasma membrane
population of CB1 receptor. These two polyclonal antibodies are designed against the
same last 31 amino acids of the CB1 receptor, thus adding a further degree of complexity
to the interpretation of these paradoxical results. Several phosphorylation sites exist at
the C-terminal of the CB1 receptor [50,51], and phosphorylation of these residues could
impact differentially the affinity of these antibodies for the epitope. Presuming that the
phosphorylation status of the CB1 receptor could differ between lipid and non-lipid rafts
domains could account for our data and would define these antibodies as tools for detecting
different states of the total population of the CB1 receptor.
In summary, to the validity of the genetic approach used to generate the CB1-RS
mouse model, our results indicated that in cortical synaptosomes, the expression levels,
the subsynaptic localization, and the plasma membrane lipid rafts versus non-lipid rafts
partition of the CB1 receptor and Gαi/o subunits, were indistinguishable from cortical
synaptosomes of the wild-type mice. The results evidence that the rescue methodology re-
stores the levels of the presynaptic CB1 receptor at the same endogenous plasma membrane
sites. Finally, to study the Gαi/o functional coupling of the CB1 receptor located in cortical
and hippocampal synaptosomal membranes, we performed [35S]GTPγS binding assays.
Agonist-stimulated [35S]GTPγS binding showed that the wild-type and the CB1-RS mice
did not differ in the efficiency of CB1 receptor coupling to Gαi/o proteins both in frontal
cortical and in hippocampal synaptosomes. Thus, besides restoring the levels of the CB1
receptor at endogenous plasma membrane sites, the Gαi/o coupling was not altered by
the set of genetic modifications that culminate in the rescue of the CB1 receptor. Therefore,
here we provided data that corroborate previous results [5–7], supporting the wild-type
phenotype of the CB1-RS mice and the suitability of the genetic approach.
In the last decade, it has been demonstrated that the functionality of the CB1 re-
ceptor depends on membrane cholesterol content and the integrity of lipid rafts [52–54].
Cholesterol negatively regulates the function of canonical signalling of the CB1 receptor
through Gαi/o proteins, because cholesterol depletion procedures increase both CB1 recep-
tor agonist high-affinity maximal binding (Bmax) as well agonist-stimulated [35S]GTPγS
binding efficacy (Emax) [54]. Therefore, it has been proposed that lipid rafts are suitable
structures for the negative regulation of the CB1 receptor function by cholesterol because
in these microdomains the presence of this lipid is significantly higher than in non-raft
plasma membranes. Indeed, strategies used to reduce membrane cholesterol levels, such
as membrane treatment with the MβCD compound, mostly deplete cholesterol from lipid
rafts, supporting this hypothesis. However, most of the information that we have about
this phenomenon has been obtained in heterologous cellular models. Therefore, to assess
this hypothesis, frontal cortical synaptosomes from both wild-type and CB1-RS mice were
treated with 10 mM of MβCD, which induced depletion of 30% of total cholesterol from
the synaptosomal plasma membrane. The increase in [35S]GTPγS-specific binding to a
maximal concentration of the CP 55,940 suggests that the CB1 receptor located in lipid
rafts of the synaptosomal membranes is probably responsible for the functional output
measured. To the best of our knowledge, this is the first time that the distribution of the
presynaptically located CB1 receptor at lipid and non-lipid raft microdomains has been
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characterized while providing robust data on the cholesterol modulation of the cannabinoid
agonist-stimulated CB1 receptor coupling to Gαi/o protein. Our experimental design does
not allow us to determine the contribution of the lipid raft and non-lipid raft-located CB1
receptors to the overall response to agonists as exposing plasma membrane material to
Triton X-100 (1%) abolishes coupling between GPCR and G proteins [55]. Due to such
technical reasons, currently, there is little data on the functional activity of GPCR-mediated
signalling in plasma membrane subdomains.
We have previously addressed the potential impact that the cellular context (gluta-
matergic versus GABAergic neurons) could exert in the canonical coupling of the presy-
naptically located CB1 receptor to Gαi/o subunits performing [35S]GTPγS binding assays
in hippocampal tissue homogenates of cell type-specific knockout mutants, Glu-CB1-KO
and GABA-CB1-KO mice [10]. Our data showed that although the level of CB1 receptors
expressed in glutamatergic neurons was significantly lower than that expressed in GABAer-
gic neurons, it was responsible for more than 50% of the maximal responses to agonists.
The results showed that in glutamatergic neurons there was a more effective CB1 receptor-
dependent Gαi/o protein signalling than in GABAergic neurons [10]. However, the results
could be affected by the CB1 receptor–Gαi/o coupling located in other subcellular com-
partments since the experiments were performed in hippocampal tissue homogenates [10].
Therefore, to study the impact that cellular context produces in the presynaptic CB1
receptor–Gαi/o protein signalling, we performed Western blots and [35S]GTPγS binding
assays in frontal cortical and hippocampal synaptosome-enriched fractions obtained from
mice that express the CB1 receptor exclusively in dorsal telencephalic glutamatergic neu-
rons (Glu-CB1-RS) [5] or in forebrain GABAergic neurons (GABA-CB1-RS) [6]. As expected,
in frontal cortical synaptosomal membranes, the specific bands resulting from the immun-
odetection of the CB1 receptor in both partial rescue mice (Glu-CB1-RS and GABA-CB1-RS)
represented about 45% of the corresponding total signal obtained in CB1-RS mice. In
contrast, the specific CB1 receptor bands in hippocampal synaptosomes of Glu-CB1-RS and
GABA-CB1-RS was about 28% and 70% of the total signal found in CB1-RS, respectively.
Thus, the sum of CB1 receptor immunoreactivity in glutamatergic and GABAergic termi-
nals of frontal cortical and hippocampal synaptosomes were found to be around 90% and
100% of the total signal of the CB1 receptors in these brain areas, respectively. Anatomical
studies have shown that CB1 receptor density in GABAergic terminals is considerably
higher than in glutamatergic terminals in almost all cortical areas [1,38,56,57]. However,
the fact that the number of excitatory terminals (80% of pyramidal glutamatergic neurons)
predominate over the inhibitory ones (20% of GABAergic interneurons) in the cerebral
cortex [58] could explain the observed absence of differences in the levels of CB1 receptor
expression in Western blots of frontal cortical synaptosomes derived from Glu-CB1-RS and
GAB-CB1-RS mice. Agonist-stimulated [35S]GTPγS binding in Glu-CB1-RS- and GABA-
CB1-RS-derived frontal cortical and hippocampal synaptosomes clearly showed that the
maximal response (Emax) to full agonists correlated with the abundance of CB1 receptors,
irrespective of the terminal type (glutamatergic or GABAergic) context. In this way, in
frontal cortical synaptosomes, an equal contribution of glutamatergic (Glu-CB1-RS) and
GABAergic (GABA-CB1-RS) CB1 receptors to the total CB1 receptor population (CB1-RS),
as defined by Western blot assays, was followed by an equal contribution to the total
agonist-stimulated CB1 receptor coupling to Gαi/o proteins, as defined by [35S]GTPγS
binding assays. Meanwhile, in hippocampal synaptosomes where 28% of the signal of the
CB1-RS was found in Glu-CB1-RS, and 70% in GABA-CB1-RS, the CB1 receptor located at
GABAergic terminals was responsible for considerably more Gαi/o protein activation than
the CB1 receptor located at glutamatergic terminals. A similar correlation between CB1
receptor-dependent Gαi/o protein signalling to agonists and the expression levels of the
CB1 receptor was also observed when cortical and hippocampal synaptosomes were com-
pared in each genotype. Thus, the expression of the CB1 receptor and agonist-stimulated
CB1 receptor coupling to Gαi/o proteins was systematically higher in hippocampal synap-
tosomes than in frontal cortical synaptosomes (both in wild-type and in CB1-RS mice).
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The concentration–response curves for the agonists tested (CP 55,940 and WIN 55,212-2)
showed similar agonist potency (pEC50) in both regions and genotypes. In addition, the
similar magnitude of the negative regulation exerted by cholesterol on agonist dependent
CB1 receptor coupling to Gαi/o proteins at both types of presynaptic terminals informs
us that probably there are no differences to the raft location of the CB1 receptor signalling
elements related to the cellular context (glutamatergic versus GABAergic neurons). In any
case, as discussed above, one of the limitations of our experimental design is that it did
not allow us to determine the contribution of the lipid raft- and non-lipid raft-located CB1
receptors to the overall response to agonists. Therefore, we can only speculate about the
increased agonist efficacy as exclusively linked to the activation of CB1 receptor located in
lipid rafts.
In conclusion, our results demonstrated the suitability of the genetic approach and
support the wild-type phenotype of the CB1-RS mice with respect to the expression level,
subsynaptic distribution, raft vs non-raft compartmentalization, and Gαi/o coupling of
CB1 receptors in synaptosomes. These findings showed that the plasma membrane parti-
tioning of the CB1 receptor and its functional coupling to Gαi/o proteins are not biased
towards the cell type of CB1 receptor rescue. In addition, we provided an updated view of
the functional coupling of the CB1 receptor to Gαi/o proteins at excitatory and inhibitory
terminals, showing that the extent of the canonical Gαi/o protein-dependent CB1 recep-
tor signalling correlated with the abundance of CB1 receptor in the respective cell type
(glutamatergic versus GABAergic neurons) both in frontal cortical and hippocampal synap-
tosomes. Moreover, we explored the effects of plasma membrane cholesterol abundance on
CB1 receptor signalling, decreasing the membrane cholesterol level by MβCD. Pretreat-
ment of synaptosomes from Glu-CB1-RS and GABA-CB1-RS mice with MβCD increased
the agonists efficacy to the same extent. In summary, the data infered here further sub-
stantiate the potential of our approach to unravel cell-type specific CB1 receptor signalling
and highlight the utility of the CB1 receptor rescue model in studying endocannabinoid
physiology on the subcellular level.
4. Materials and Methods
4.1. Animal Procedures and Brain Tissue Preparation
All experimental protocols were performed in accordance with the European Com-
munity’s Council Directive of 24 November 1986 (86/609/EEC. Animals were housed in a
temperature- and humidity-controlled room (22 ± 1 ◦C; 50 ± 1%) with a 12 h light/dark
cycle (lights on at 7:00 A.M.) and had access to food and water ad libitum. This study
was performed on adult (16–26 weeks old) male mice from the following mouse lines:
conventional CB1 receptor knockout (CB1-KO) mice and wild-type (WT) littermates, Stop-
CB1 mice and their Glu-CB1 receptor rescue (Glu-CB1-RS) littermates, Stop-CB1 and their
GABA-CB1 receptor rescue (GABA-CB1-RS) littermates and the CB1 receptor total rescue
(CB1-RS) mice. Stop-CB1 mice and the CB1 receptor total rescue (CB1-RS) mice were
produced by separate breedings as the general deleter EIIα-Cre [59] caused mosaicism in
the offspring. Stop-CB1 mice were generated by heterozygous breeding of CB1stop/+ mice.
CB1-RS mice, on the other hand, were obtained by homozygous breeding of mice carrying
the recombined floxed Stop-CB1 allele. The reader is referred to previous studies for more
detailed information on generation, breeding, and genotyping of the mice [3,5,6,60].
Mice were anesthetized with isoflurane (10 s) before decapitation. For brain extraction,
the skull was cut with a scissor and the complete brain was carved out with a spatula.
Then, blood clots and the meninges were removed from the sample and the piece was
dissected carefully to obtain different brain regions. Initially, a sagittal incision was made
in the central part of the brain to allow the separation of the cerebral hemispheres. Once
those were completely separated, the hippocampus and the frontal cortex were separated
from the diencephalon and basal ganglia. After removing white matter from the cortical
sample as much as possible, tissue was stored at −80 ◦C until use.
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4.2. Chemicals and Antibodies
All chemicals and reagents are described in the Supplementary file. Supplementary
Table S1 contains the list of the antibodies used.
4.3. Preparation of Mouse Synaptosomal Membranes and Purification of Subsynaptic Fractions
Synaptosomal membranes from the hippocampus and frontal cortex were prepared
as previously described by Dodd et al. (1981) [61] with slight modifications made by our
laboratory [62]. Pooled hippocampal and cortical tissue from eight mice (about 500 mg–1 g
fresh tissue weight per fractionation procedure) was thawed slowly on ice-cold 0.32 M
sucrose, pH 7.4, containing 80 mM Na2HPO4 and 20 mM NaH2PO4 (sucrose phosphate
buffer). The tissue was minced and homogenized in 10 volumes of sucrose/phosphate
buffer, using a motor-driven Potter Teflon glass homogenizer (motor speed 800 rpm; 10 up
and down strokes; mortar cooled in an ice-water mixture throughout). The homogenate
was centrifuged at 1000× g for 10 min. The supernatant S1 was pelleted at 15,000× g for
30 min. The obtained pellet (P2 crude) was resuspended in an adequate volume of the
same buffer, and a 100 µL aliquot was used for protein determination using the Bio-Rad
dye reagent with bovine γ-globulin as standard. The crude membrane suspension was
pelleted at 15,000× g for 30 min and resuspended to obtain 16 mL of a suspension with
a total protein concentration of 2.5–4 mg/mL. This P2 suspension was layered onto a
centrifugation tube and 8 mL of 1.2 M sucrose phosphate buffer was added on the bottom
of the tube using a Pasteur pipette, and centrifuged at 180,000× g for 15 min. The material
retained at the gradient interface (synaptosomes + myelin + microsomes) was carefully
collected with a Pasteur pipette and diluted with ice-cold 0.32 M sucrose/phosphate buffer
to a final volume of 16 mL. The diluted suspension was then layered onto 8 mL of 0.8 M
sucrose buffer containing 80 mM Na2HPO4 and 20 mM NaH2PO4, and centrifuged as
described above. The pellet obtained was resuspended in an adequate volume of phosphate
buffer (pH 7.4) to give a synaptosome suspension with a total protein concentration of
1.5–3 mg/mL. Aliquots were then centrifuged at 40,000× g for 30 min, the supernatants
were aspirated and the synaptosomal pellets were frozen at −80 ◦C. Protein content was
determined using the Bio-Rad dye reagent with bovine γ-globulin as standard.
The separation of the presynaptic active zone (PAZ), postsynaptic density (PSD) and
non-synaptic fractions (extrasynaptic, EXTRA) from cortical nerve terminals was carried
out as initially described by Phillips et al. (2001) [11]. Cortical synaptosomal membranes
(4–5 mg total protein) were diluted in 10 mL of solubilization buffer (1% Triton X-100,
20 mM Tris, 0.1 mM CaCl2, pH 6.0), and were incubated for 30 min on ice with mild
agitation, and the insoluble material (synaptic junctions-PAZ+PSD) pelleted (40,000× g
for 30 min at 4 ◦C). The supernatant (EXTRA fraction) was decanted, and the contained
proteins precipitated with six volumes of acetone at −20 ◦C. Finally, the EXTRA fraction
was recovered by centrifugation (18,000× g for 30 min at 4 ◦C). The synaptic junction
(PAZ + PSD) pellet was resuspended in 10 mL of a solubilization buffer (1% Triton X-100,
20 mM Tris, pH 8.0). After incubation for 30 min on ice with mild agitation, the mixture was
centrifuged (18,000× g for 30 min at 4 ◦C), and the supernatant (presynaptic fraction-PAZ)
processed as described for the extrasynaptic fraction. The pellets from the supernatants
and the final insoluble pellet (postsynaptic fraction-PSD) were solubilized in 5% SDS, and
the total protein concentration determined by the bicinchoninic acid (BCA) protein assay
following the Abcam’s BCA Protein Quantification Kit procedure.
4.4. Isolation of “Lipid Rafts” from Cortical Synaptosomal Membranes
Cortical synaptosomal aliquots (6 mg total protein) were solubilized at 4 ◦C with 2 mL
of sodium phosphate buffer containing 1% Triton X-100 by end-over-end mixing (30 min).
Thereafter, the extracts are adjusted to 45% sucrose, and overlaid with 4 mL of 35% sucrose
in sodium phosphate buffer, and 4 mL of 5% sucrose in sodium phosphate buffer, inside
an ultracentrifugation tube. Lipid raft fractions were isolated by ultracentrifugation at
140,000× g, for 18 h, 4 ◦C. Then gradient was harvested in 12 fractions of 1 mL each plus the
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pellet. The analysis of lipid raft (Thy-1, and flotillin)/non-raft fractions (Na+/K+-ATPase)
markers were carried out in different gels using the same volume per gel of samples
from each of the fractions from the same separation. The Alkaline Phosphatase Assay Kit
(ab83369) from Abcam was used to determine the alkaline phosphatase (ALP) activity in
lipid raft and non-raft fractions derived from synaptosomes.
4.5. Immunofluorescence Assay for Frontal Cortical Synaptosomes
Immunofluorescence assays were performed as previously described with minor
modifications [63]. Details of the procedure are described in the Supplementary Methods.
4.6. Treatment of Cortical Synaptosomal Fractions with Deglycosylating Enzymes
PNGase F enzymatic method (New England BioLabs) was used for removing N-
linked oligosaccharides from glycoproteins. PNGase F is an amidase, which cleaves
between the innermost GlcNAc and asparagine residues of high mannose, hybrid and
complex oligosaccharides. Briefly, Nine parts of 2.3 µg/µL of synaptosomes re-suspended
in phosphate buffer were combined with one part of 10× Glycoprotein Denaturing Buffer
(5% SDS, 400 mM DTT). Glycoproteins were denatured by heating the reaction at 60 ◦C for
10 min. Thereafter, the denatured sample was mixed in a 1:1 ratio with 2× GlycoBuffer 2
and 2% NP-40 diluted in H2O. Finally, 1 µL of PNGase F was added per each 20 µg of total
protein of the denatured synaptosomal fraction, and the reaction mixture was incubated at
37 ◦C for 1 h. The extent of deglycosylation of the CB1 receptor was assessed by mobility
shifts on SDS-PAGE gel by Western blot assays.
4.7. Treatment of Cortical Synaptosomes with Methyl-β-cyclodextrin
Methyl-β-cyclodextrin (MβCD) compound was used to directly extract cholesterol
from synaptic plasma membranes. Several preliminary experiments were conducted
to determine the optimal concentration of MβCD to deplete cholesterol from cortical
synaptosomal membranes. Synaptosomes (1 mg protein/mL) were incubated with the
indicated concentration of MβCD on 50 mM Tris-HCl buffer (pH 7.4) for 30 min at 37 ◦C.
After treatment, the reaction was stopped by adding a large volume of cold Tris-HCl buffer
without MβCD, and synaptosomes were pelleted at 15,000× g for 15 min at 4 ◦C. The
obtained pellet was re-suspended again in a Tris-HCl buffer without MβCD and aliquoted
in microcentrifuge tubes. Aliquots were then centrifuged at 15,000× g for 30 min and pellets
corresponding to synaptosomes were stored at −80 ◦C. The Cholesterol Assay Kit (ab65359)
from Abcam was used to determine total cholesterol level of synaptosomal membranes.
4.8. Western Blot Assay in Purified Fractions of Synaptosomal Membranes
Western blot experiments were performed as previously described with minor modifi-
cations [20,62]. The procedure is described in the Supplementary Methods.
4.9. Agonist Stimulated [35S]GTPγS Binding Assay in Synaptosomal Membranes
The [35S]GTPγS binding assays were performed following the procedure described
elsewhere [64] with minor modifications. Detailed experimental protocol is presented in
the Supplementary Methods.
Supplementary Materials: The following supplementary material is available online, Supplementary
materials and methods [65,66]; Figure S1: Western blot of the homogenate and subcellular fractions
obtained from sequential fractionation of adult mouse brain cortical homogenates; Figure S2: Double-
immunofluorescence MAP2/GFAP and SNAP25/GFAP combined with the membrane marker DiIC16
in isolated cortical synaptosomes maintained in isotonic buffer and seeded on poly-L-ornitine coated
coverslip; Figure S3: Migration profile of the CB1 receptor immunorreactive bands in synaptosome
samples subjected to a potentially proteolytic condition and to an N-glycosidase treatment with the
PNGase F enzyme; Figure S4: Subsynaptic compartmentalization of the protein selected markers in
PAZ, PSD and EXTRA fractions isolated from cortical synaptosomes derived from wild-type mice;
Figure S5: Subsynaptic compartmentalization of the protein selected markers in PAZ, PSD and EXTRA
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fractions isolated from cortical synaptosomes derived from CB1-RS mice; Figure S6: Subsynaptic
compartmentalization of the CB1 receptor, the canonical transducers coupled to CB1 receptors
and other proteins of the endocannabinoid system in PAZ, PSD and EXTRA fractions isolated from
cortical synaptosomes derived from CB1-RS mice; Figure S7: Alkaline phosphatase enzymatic activity,
total protein amount and distribution of raft and non-raft markers in lipid raft and non-lipid raft
fractions isolated from frontal cortical synaptosomes derived from CB1-RS mice. Figure S8: CB1
receptor protein expression in synaptosomes obtained from frontal cortical and hippocampal tissue
of wild-type, CB1-RS and Stop-CB1 mice; Figure S9: CB1 receptor coupling to Gαi/o proteins in
synaptosomes obtained from frontal cortical and hippocampal tissue of wild-type and CB1-RS mice;
Figure S10: CB1 receptor coupling to Gαi/o proteins in control and in 5 mM, 10 mM and 20 mM
MβCD pretreated synaptosomes from frontal cortical tissue of Glu-CB1-RS and GABA-CB1-RS
mice; Figure S11: Model for the phosphorylation-dependent electrophoretic mobility shift (PDEMS)
phenomenon and the EMS-related motif. Adapted from Figure 4 in Lee et al. (2019) [31]; Table S1:
The list of primary antibodies used; Table S2: Migration profile of the CB1 receptor immunorreactive
bands in synaptosome samples obtained in the absence or the presence of protease inhibitors during
the fractionation procedure; Table S3: Statistical analysis of the subsynaptic distribution of the CB1
receptor immunoreactive signals of ~50 kDa and ~35 kDa bands between CB1-RS and wild-type mice
(WT); Table S4: Densitometry analysis of the specific immunorreactive signals (~50 kDa and ~35kDa
bands) of the CB1 receptor (see Supplemental Figure S8), normalized to the signal of frontal cortical
synaptosomes of wild-type; Table S5: Concentration–response curves for the CP 55,940-stimulated
specific [35S]GTPγS binding in frontal cortical and hippocampal synaptosomes derived from wild-
type (WT) and CB1-RS mice; Table S6: CB1 receptor protein expression in synaptosomal membranes
of frontal cortex by the slope comparison method of the lines obtained by regression analysis of
the data shown in the Figure 4B–D; Table S7: Stimulation of [35S]GTPγS binding by a maximal
concentration (10 µM) of the cannabinoid agonist CP 55,940 in cortical synaptosomes from wild-type
mice pretreated with MβCD as described in Section 4.7 from Materials and Methods; Table S8:
Stimulation of [35S]GTPγS binding by a maximal concentration (10 µM) of the cannabinoid agonists
CP 55,940 and WIN 55,212-2 in cortical synaptosomes from Glu-CB1-RS and GABA-CB1-RS mice
pretreated with MβCD (10 mM) as described in Section 4.7 from Materials and Methods. Table S9:
Summary table of the CB1 receptor density and the CB1 receptor coupling to Gαi/o in cortical and
hippocampal synaptosomes from wild-type (WT), CB1-RS, Glu-CB1-RS and GABA-CB1-RS mice.
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